RAIN logo

Rain Therapeutics (RAIN) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

23 April 2021

Indexes:

Not included

Description:

As of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Mar 08, 2024

Recent annual earnings:

Mar 08, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

18 Sept '23 Citigroup
Neutral
05 June '23 Mizuho
Neutral
02 June '23 Roth MKM
Neutral
02 June '23 HC Wainwright & Co.
Neutral
30 May '23 Roth MKM
Neutral
30 May '23 EF Hutton
Hold
23 May '23 Piper Sandler
Neutral
23 May '23 Oppenheimer
Perform
23 May '23 JonesTrading
Hold
23 May '23 HC Wainwright & Co.
Neutral

Screeners with RAIN included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

Rain Oncology Inc. (RAIN) Q2 2023 Earnings Call Transcript
Rain Oncology Inc. (RAIN) Q2 2023 Earnings Call Transcript
Rain Oncology Inc. (RAIN) Q2 2023 Earnings Call Transcript
RAIN
Seeking Alpha10 August 2023

Rain Oncology Inc. (NASDAQ:RAIN ) Q2 2023 Earnings Call Transcript August 10, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Nelson Cabatuan - Acting SVP, Finance Robert Doebele - CSO Conference Call Participants Ashiq Mubarack - Citigroup Joe Catanzaro - Piper Sandler Anshul Dhankher - LifeSci Capital Avantika Joshi - Mizuho Securities Mitchell Kapoor - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Rain Oncology Inc. Second Quarter 2023 Earnings Conference Call.

Why Is RAIN Stock Down 87% Today?
Why Is RAIN Stock Down 87% Today?
Why Is RAIN Stock Down 87% Today?
RAIN
InvestorPlace22 May 2023

Rain Oncology (NASDAQ: RAIN ) stock is taking a massive beating on Monday after the company revealed its latest clinical trial data. The bad news for investors in RAIN stock is the company's Phase 3 MANTRA trial failed to meet its primary endpoint.

Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Call Transcript
Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Call Transcript
Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Call Transcript
RAIN
Seeking Alpha13 May 2023

Rain Oncology, Inc. (NASDAQ:RAIN ) Q1 2023 Earnings Conference Call May 11, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Robert Doebele - CSO Richard Bryce - CMO Nelson Cabatuan - SVP, Finance Conference Call Participants Yigal Nochomovitz - Citigroup Michael Schmidt - Guggenheim Joe Catanzaro - Piper Sandler Soumit Roy - Jones Trading Sam Slutsky - LifeSci Capital Jeff Jones - Oppenheimer Faisal Khurshid - SVB Securities Mitchell Kapoor - H.C. Wainwright Avantika Joshi - Mizuho Securities Tony Butler - EF Hutton Operator Greetings, and welcome to the Rain Oncology, Inc. First Quarter 2023 Earnings Call.

Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data
Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data
Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data
RAIN
Seeking Alpha27 April 2023

Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data.

Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023
Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023
Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023
RAIN
Seeking Alpha26 April 2023

Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023.

FAQ

  • What is the primary business of Rain Therapeutics?
  • What is the ticker symbol for Rain Therapeutics?
  • Does Rain Therapeutics pay dividends?
  • What sector is Rain Therapeutics in?
  • What industry is Rain Therapeutics in?
  • What country is Rain Therapeutics based in?
  • When did Rain Therapeutics go public?
  • Is Rain Therapeutics in the S&P 500?
  • Is Rain Therapeutics in the NASDAQ 100?
  • Is Rain Therapeutics in the Dow Jones?
  • When was Rain Therapeutics's last earnings report?
  • When does Rain Therapeutics report earnings?
  • Should I buy Rain Therapeutics stock now?

What is the primary business of Rain Therapeutics?

As of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.

What is the ticker symbol for Rain Therapeutics?

The ticker symbol for Rain Therapeutics is NASDAQ:RAIN

Does Rain Therapeutics pay dividends?

No, Rain Therapeutics does not pay dividends

What sector is Rain Therapeutics in?

Rain Therapeutics is in the Healthcare sector

What industry is Rain Therapeutics in?

Rain Therapeutics is in the Biotechnology industry

What country is Rain Therapeutics based in?

Rain Therapeutics is headquartered in United States

When did Rain Therapeutics go public?

Rain Therapeutics's initial public offering (IPO) was on 23 April 2021

Is Rain Therapeutics in the S&P 500?

No, Rain Therapeutics is not included in the S&P 500 index

Is Rain Therapeutics in the NASDAQ 100?

No, Rain Therapeutics is not included in the NASDAQ 100 index

Is Rain Therapeutics in the Dow Jones?

No, Rain Therapeutics is not included in the Dow Jones index

When was Rain Therapeutics's last earnings report?

Rain Therapeutics's most recent earnings report was on 8 March 2024

When does Rain Therapeutics report earnings?

The date for Rain Therapeutics's next earnings report has not been announced yet

Should I buy Rain Therapeutics stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions